Alnylam Pharmaceuticals (NasdaqGS:ALNY) recently announced the appointment of Dr. Pushkal Garg as Executive Vice President and Chief Research and Development Officer to accelerate its R&D efforts.

The European Commission Approves Alnylam’s AMVUTTRA. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9, ...

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated ...

Pfizer’s 7%+ yield is tempting, but rising political, regulatory, and business risks threaten its stability and growth ...

Alnylam joins three-way contest in ATTR cardiomyopathy. Alnylam has claimed FDA approval for Amvuttra in ATTR cardiomyopathy, allowing it to compete with rival therapies from Pfizer and BridgeBio.

Alnylam's choice of words in its update suggests it may consider developing an alternative RNAi drug for Stargardt disease, avoiding the price negotiation trigger for Amvuttra altogether. Overall ...

The approach could enable 30-minute testing for a heart condition that is newly treatable following recent drug approvals.

The Inflation Reduction Act includes an exemption for orphan drugs for a single indication, but experts say this is far from ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.